Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H41NO6S |
| Molecular Weight | 507.683 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\C3=CSC(C)=N3
InChI
InChIKey=QXRSDHAAWVKZLJ-PVYNADRNSA-N
InChI=1S/C27H41NO6S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)33-23(30)13-21(29)26(5,6)25(32)17(3)24(15)31/h11,14-15,17,20-22,24,29,31H,8-10,12-13H2,1-7H3/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1
| Molecular Formula | C27H41NO6S |
| Molecular Weight | 507.683 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugbank.ca/drugs/DB03010Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT00262990 | https://clinicaltrials.gov/ct2/show/NCT00273312 | https://www.ncbi.nlm.nih.gov/pubmed/27872763 | https://www.ncbi.nlm.nih.gov/pubmed/15860865
Sources: https://www.drugbank.ca/drugs/DB03010
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT00262990 | https://clinicaltrials.gov/ct2/show/NCT00273312 | https://www.ncbi.nlm.nih.gov/pubmed/27872763 | https://www.ncbi.nlm.nih.gov/pubmed/15860865
Patupilone is a compound isolated from the myxobacterium Sorangium cellulosum. Similar to paclitaxel, Patupilone induces microtubule polymerization and stabilizes microtubules against depolymerization conditions. In addition to promoting tubulin polymerization and stabilization of microtubules, this agent is cytotoxic for cells overexpressing P-glycoprotein, a characteristic that distinguishes it from the taxanes. Epothilone B may cause complete cell-cycle arrest. Patupilone failed a phase III trial for ovarian cancer in 2010.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2095182 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15060743 |
4.7 µM [IC50] | ||
Target ID: CHEMBL1848 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16134928 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
139 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19451434 |
11 mg/m² single, intravenous dose: 11 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PATUPILONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1386 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19451434 |
11 mg/m² single, intravenous dose: 11 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PATUPILONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
100 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19451434 |
11 mg/m² single, intravenous dose: 11 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
PATUPILONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/20966043/ |
no | |||
| no | ||||
| weak [IC50 25 uM] | no (co-administration study) Comment: S-warfarin Cmax and AUC(0-168h) were increased by 2% and 8%. Sources: https://pubmed.ncbi.nlm.nih.gov/21220503/ |
|||
| yes [EC50 12.6 uM] | ||||
| yes [IC50 5 uM] | no (co-administration study) Comment: Omeprazole Cmax and AUC(0-12h) were decreased by 21% and 19%. Sources: https://pubmed.ncbi.nlm.nih.gov/21499896/ |
|||
| yes [IC50 5 uM] | no (co-administration study) Comment: Midazolam Cmax was reduced by 33% and AUC(0-12h) was increased by 1%. Sources: https://pubmed.ncbi.nlm.nih.gov/21499896/ |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| major | ||||
| no | ||||
| yes |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24937505
Patupilone (Novartis, Basel, Switzerland) was administered
every 3 weeks either as a bolus (20 min), 1-day continuous infusion
(24 h) or 5-day continuous infusion (16-h per day over 5 days) at dose
levels of 6.5, 7.0, 7.5, 8.0, 9.0 and 10.0 mg/m2 until disease progression,
unacceptable toxicity or withdrawal of consent.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27872763
Cortices were dissected from embryonic 15.5mice and incubated in papain (20U/mL, Worthington) containing DNase (10 U/𝜇L, Sigma) for 40min at 37∘C. Enzyme-digested cortices were washed three times with MEM (Cellgro) containing 10% heat inactivated fetal bovine serum (Hyclone) and dissociated in culture medium. Dissociated neurons were then centrifuged to remove the supernatant and counted cells were plated on glass coverslips coated with 100 𝜇g/mL poly-D-lysine (Sigma) and grown in Neurobasal A (Gibco) medium containing Glutamax (1%, Thermo Fisher Scientific) and B27 (2%, Thermo Fisher Scientific) supplements. 5 hr after plating, neurons were treated with epothilone B (from 1 pM to 1 𝜇M and 10pM or 1 nM) for 3 days in low-density cultures (5 x 104 cells in 1.9 cm2) or overnight (17–19hr) in high-density cultures (2 x 105 cells in 1.9 cm2). Neurons were then fixed and analyzed for viability, axon growth, and microtubule structure.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:22:09 GMT 2025
by
admin
on
Mon Mar 31 19:22:09 GMT 2025
|
| Record UNII |
UEC0H0URSE
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
298809
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
||
|
FDA ORPHAN DRUG |
210205
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
||
|
NCI_THESAURUS |
C1922
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
||
|
NCI_THESAURUS |
C67437
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
||
|
FDA ORPHAN DRUG |
298909
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/09/687
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C093788
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
PRIMARY | |||
|
CHEMBL94657
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
PRIMARY | |||
|
448013
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
PRIMARY | |||
|
C1623
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
PRIMARY | |||
|
8320
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
PRIMARY | |||
|
152044-54-7
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
PRIMARY | |||
|
UEC0H0URSE
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
PRIMARY | |||
|
m4954
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB03010
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
PRIMARY | |||
|
100000126141
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
PRIMARY | |||
|
DTXSID4046862
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
PRIMARY | |||
|
31550
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
PRIMARY | |||
|
SUB33376
Created by
admin on Mon Mar 31 19:22:09 GMT 2025 , Edited by admin on Mon Mar 31 19:22:09 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
DERIVATIVE -> PARENT |
|
||
|
TARGET->LIGAND |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|